Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma reported full-year 2025 revenue of SEK 152.4 million, with higher Ximluci product sales and license income contributing to a swing to a SEK 127.2 million profit from a large loss a year earlier, mainly driven by a gain from its Alvotech transaction. The company strengthened its balance sheet with an equity ratio of 83 percent, implemented a major share consolidation and capital reduction to clean up past losses, and opted against a dividend as it continues to prioritize R&D spending.
Operationally, Ximluci’s end-customer sales in Europe rose 63 percent in 2025, though Xbrane’s quarterly revenues remained volatile due to irregular deliveries to STADA and ongoing investments to lower production costs, expected to pay off from 2027. The firm is preparing to resubmit its ranibizumab biosimilar application to the FDA in March 2026 after addressing manufacturing observations cited in a Complete Response Letter, while advancing its Xdivane program with ongoing clinical recruitment and process scale-up ahead of a planned FDA filing in late 2027.
To bolster liquidity and flexibility, Xbrane entered into a conditional financing agreement with Fenja Capital II A/S, including a warrant issue linked to that facility. Management emphasizes that progress in its key development programs and forthcoming regulatory milestones are central to its strategy of consolidating its position in the global biosimilars market, with implications for future U.S. market entry and long-term growth prospects for shareholders and partners.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK10.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a Swedish biotechnology company focused on developing and commercializing biosimilars, with a particular emphasis on ophthalmology and immuno-oncology. Its key marketed product is Ximluci, a ranibizumab biosimilar for retinal diseases, commercialized with partner STADA mainly in the European market, while pipeline candidate Xdivane targets immune checkpoint inhibition.
Average Trading Volume: 57,438
Technical Sentiment Signal: Sell
Current Market Cap: SEK211.2M
For detailed information about XBRANE stock, go to TipRanks’ Stock Analysis page.